Browsing by author "Melcher, Alan"
Now showing items 41-60 of 61
-
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
Melake, MJ; Smith, HG; Mansfield, D; Davies, E; Dillon, MT; et al. (TAYLOR & FRANCIS INC, 2022-12-31)Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates. ... -
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith, HG; Mansfield, D; Roulstone, V; Kyula-Currie, JN; McLaughlin, M; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor monotherapy has shown little activity in sarcoma and there is great interest in identifying novel ... -
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation.
Murray, J; Cruickshank, C; Bird, T; Bell, P; Braun, J; et al. (ELSEVIER IRELAND LTD, 2022-11-01)PEARLS is a multi-stage randomised controlled trial for prostate cancer patients with pelvic and/or para-aortic PSMA-avid lymph node disease at presentation. The aim of the trial is to determine whether extending the ... -
Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.
Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; et al. (2018-04) -
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Annels, NE; Mansfield, D; Arif, M; Ballesteros-Merino, C; Simpson, GR; et al. (AMER ASSOC CANCER RESEARCH, 2019-10-01)PURPOSE: The CANON [CAVATAK in NON-muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. PATIENTS AND METHODS: ... -
Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors.
Schuelke, MR; Gundelach, JH; Coffey, M; West, E; Scott, K; et al. (OXFORD UNIV PRESS, 2022-01-01)BACKGROUND: Brain tumors are the leading cause of cancer death for pediatric patients. Pelareorep, an immunomodulatory oncolytic reovirus, has intravenous efficacy in preclinical glioma models when preconditioned with ... -
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller, LME; Holmes, M; Michael, JL; Scott, GB; West, EJ; et al. (BMJ PUBLISHING GROUP, 2019-07-01)BACKGROUND: The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer ... -
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings, VA; Scott, GB; Rose, AMS; Scott, KJ; Migneco, G; et al. (CELL PRESS, 2019-06-05)A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and ... -
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett, E; Kottke, T; Thompson, J; Rajani, K; Zaidi, S; et al. (NATURE PUBLISHING GROUP, 2017-01-01)The anti-tumour effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms, which depend both on the type of virus and the route of delivery. Here, we show that intra-tumoral ... -
Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.
Wilkins, A; McDonald, F; Harrington, K; Melcher, A (BMC, 2019-03-06)Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-small cell ... -
RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.
Wilkins, A; Hall, E; Lewis, R; Gribble, H; Melcher, A; et al. (ELSEVIER SCIENCE LONDON, 2022-07-01) -
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller, LME; Migneco, G; Scott, GB; Down, J; King, S; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Multiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct ... -
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
Smith, HG; Jamal, K; Dayal, JH; Tenev, T; Kyula-Currie, J; et al. (WILEY, 2020-06-08)Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ... -
Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology.
Wilkins, A; Melcher, A; Somaiah, N (ELSEVIER SCIENCE LONDON, 2018-10-01) -
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Evgin, L; Huff, AL; Kottke, T; Thompson, J; Molan, AM; et al. (AMER ASSOC CANCER RESEARCH, 2019-05-01)Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). ... -
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Kottke, T; Evgin, L; Shim, KG; Rommelfanger, D; Boisgerault, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-11-01)Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition ... -
Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins, C; Simpson, GR; Rogers, W; Relph, K; Harrington, K; et al. (NATURE PUBLISHING GROUP, 2018-05-01)There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress ... -
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta, M; Jennings, VA; Melcher, AA; Lise, S (FRONTIERS MEDIA SA, 2020-10-08)Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation properties of mutations that ... -
The immunological consequences of radiation-induced DNA damage.
Wilkins, AC; Patin, EC; Harrington, KJ; Melcher, AA (WILEY, 2019-04-01)Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell-autonomous mechanisms of cell death. Here, tumour cell death occurs when a threshold number of radiation-induced non-reparable ... -
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
McLaughlin, M; Pedersen, M; Roulstone, V; Bergerhoff, KF; Smith, HG; et al. (CELL PRESS, 2020-03-27)Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...